ANCA Associated Vasculitis
34
12
15
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.8%
3 terminated out of 34 trials
57.1%
-29.4% vs benchmark
12%
4 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (34)
PR3-AAV Resilient Remission or PRRR
Hydroxychloroquine in ANCA Vasculitis Evaluation
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS
Early-access Avacopan in Real-world ANCA-associated Vasculitis
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV
Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis